In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement.
about
Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65-/- knockout mouse eye results in limited rescueSynaptogenesis and outer segment formation are perturbed in the neural retina of Crx mutant miceA comprehensive review of retinal gene therapyGenetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutionsReversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transferEvaluation of a behavioral method for objective vision testing and identification of achromatopsia in dogs.RPE65: role in the visual cycle, human retinal disease, and gene therapy.The retinal pigment epithelium in health and diseaseScavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular diseaseDifferential proteomics and functional research following gene therapy in a mouse model of Leber congenital amaurosisHistopathology and functional correlations in a patient with a mutation in RPE65, the gene for retinol isomerase.Nordic research in ophthalmology.Functional and anatomic consequences of subretinal dosing in the cynomolgus macaqueLeber congenital amaurosis: a genetic paradigm.Stem cells for retinal degenerative disorders.Advances in the molecular understanding of canine retinal diseases.Gene therapy progress and prospects: the eye.Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agentsLong-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.Investigation of SLA4A3 as a candidate gene for human retinal diseaseRescue of sight by gene therapy - closer than it may appear.Progress and prospects: gene therapy clinical trials (part 1).Inherited diseases of photoreceptors and prospects for gene therapy.Advances in Gene Therapy for Diseases of the Eye.Assessment of visual function and retinal structure following acute light exposure in the light sensitive T4R rhodopsin mutant dogNonviral ocular gene therapy: assessment and future directions.AAV retinal transduction in a large animal model species: comparison of a self-complementary AAV2/5 with a single-stranded AAV2/5 vector.Pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.Advances in gene therapy technologies to treat retinitis pigmentosa.The use of canine models of inherited retinal degeneration to test novel therapeutic approaches.Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis.Adeno-associated virus (AAV) based gene therapy for eye diseases.Dog models for blinding inherited retinal dystrophiesLung gene therapy-How to capture illumination from the light already present in the tunnel.AAV-mediated Gene Therapy Halts Retinal Degeneration in PDE6β-deficient Dogs.Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates.Gene delivery to the retina: from mouse to man.Gene therapy in the second eye of RPE65-deficient dogs improves retinal functionReproducibility of an objective four-choice canine vision testing technique that assesses vision at differing light intensities.Long-term preservation of retinal function in the RCS rat model of retinitis pigmentosa following lentivirus-mediated gene therapy.
P2860
Q24802168-C58F85CB-C7D1-47B8-A83B-3EBDA8B736C5Q24803520-EC36B8D5-20B0-4792-BDBA-6E5F32F3F4FCQ27023914-1EFC8134-97B4-4046-B4D5-C164BC040595Q28237552-A2B99EC7-E3E1-4FC1-9B54-1BC4BCEF937DQ33315634-4E6A1BD7-A78A-4EAE-BAB2-25F776FB8EA8Q33621931-5B9D9BA6-FC5E-4AF5-8D18-B73D215BDBDAQ33652414-CCE0028A-41C7-4917-95E6-D4FD67EAFEE5Q33998365-14DED2DA-1432-4AF0-BE4B-E46DD7DDCC94Q34218552-D5C5FBC1-D3C6-4F9B-9E43-C921F998EF0FQ34406815-B5406FC6-3673-4414-AC1E-93CAF7866217Q35524221-4320A2D2-EE96-422E-8925-C13FC1C1E858Q35594451-597D83A7-36F0-466F-A283-88485F3F8380Q35663467-172E83ED-7D2A-480E-A054-5FBD08CA9056Q35888828-BA89ADEB-93C0-4587-A57B-CFC78248579AQ36167466-7307915E-0A97-4215-B30D-6F2826F7AD0FQ36239329-69A8946B-4634-47CE-AB53-FC5FBF2D9094Q36534765-F933AA8B-3DCD-4C24-8C31-0105C43F7F9AQ36591612-4A3531E9-C4F5-42A7-A373-2C2ACABA2390Q36825024-571FC4C3-54F8-4F72-82D2-1CB35FE42CC4Q36925839-7145DB69-2DBE-4140-97A3-B6D020EB1C93Q36951825-D26CB979-1F1C-48B8-ACF3-18531E39FA97Q36957474-D1C9FF7E-E131-4D3D-A34D-0DB1FC936C1DQ37096060-8500BDED-CE52-4026-9F78-88ED2C53351DQ37190609-440FE457-DD24-4130-84D1-6E934D76F90BQ37217166-651C287A-707D-4698-BE83-4E7CFADCD125Q37284890-D5F0299C-5E6D-429A-9DB4-BF875D20C7F4Q37346460-C4D32191-0017-40A5-A84F-3AA96762C7CAQ37353812-1E9F5366-5919-4D5A-9A2B-E98731F1CF2FQ37427526-4A14FD45-70F1-4C0F-B255-2D0A0AE8A1ADQ37458980-901453CA-C9D7-4E8E-A6AC-78B71C2389EAQ37836902-1094B3F3-CD46-46A0-AB16-43296991D860Q37846117-2689C6A8-633D-4C62-BD48-D706B4EDCCCAQ38351811-B3CDE3EC-6949-4AE4-BDB2-6D7FD3D4F2B0Q38544793-7C26A243-AC6C-4C9D-88BC-6ED9D8D4F751Q38910623-14A4556B-A58A-486B-8EF6-0E1291562764Q39504342-63B0A668-3264-4671-B146-F5DE51E83CE4Q40820678-224923ED-C5C6-4713-86D6-4ADE79E7D892Q41835416-D384C2E5-810F-485B-91BA-F646D3CA8BF4Q42675128-AB38DE3A-7B62-4E4F-8A8D-E8B70FEF30F0Q45230950-C24C629A-E6FC-4483-BA4E-E1C886B4EC65
P2860
In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
In vivo gene therapy in young ...... long-term visual improvement.
@en
type
label
In vivo gene therapy in young ...... long-term visual improvement.
@en
prefLabel
In vivo gene therapy in young ...... long-term visual improvement.
@en
P2093
P356
P1433
P1476
In vivo gene therapy in young ...... s long-term visual improvement
@en
P2093
P356
10.1093/JHERED/ESG015
P577
2003-01-01T00:00:00Z